
IPO
CGEM.NASDAQ
Past
Cullinan Management
Developer of an externally sourced cancer therapeutics used to end a drug program quickly
Company websiteTicker
CGEM.NASDAQ
Market
us
Foundation year
2017
Close date
2/7/2021
IPO date
1/7/2021
Placement price
$21
Profitability
72.33%
About
Total Funding
$389.7M
Cullinan Oncology is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.
Number of employees
11-50
Headquarters
Cambridge, Massachusetts, United States